Applied Finance Capital Management LLC Sells 2,246 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Applied Finance Capital Management LLC cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,835 shares of the biopharmaceutical company’s stock after selling 2,246 shares during the period. Applied Finance Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $13,008,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of REGN. Procyon Advisors LLC boosted its position in Regeneron Pharmaceuticals by 102.0% during the first quarter. Procyon Advisors LLC now owns 889 shares of the biopharmaceutical company’s stock valued at $687,000 after acquiring an additional 449 shares during the last quarter. Citizens Financial Group Inc. RI grew its position in Regeneron Pharmaceuticals by 23.7% in the 1st quarter. Citizens Financial Group Inc. RI now owns 4,775 shares of the biopharmaceutical company’s stock worth $3,689,000 after purchasing an additional 916 shares in the last quarter. Fifth Third Bancorp lifted its position in shares of Regeneron Pharmaceuticals by 126.3% during the 1st quarter. Fifth Third Bancorp now owns 34,910 shares of the biopharmaceutical company’s stock worth $26,973,000 after buying an additional 19,485 shares in the last quarter. Simplicity Wealth LLC lifted its stake in Regeneron Pharmaceuticals by 12.1% in the first quarter. Simplicity Wealth LLC now owns 947 shares of the biopharmaceutical company’s stock valued at $731,000 after purchasing an additional 102 shares during the last quarter. Finally, Osprey Private Wealth LLC raised its position in shares of Regeneron Pharmaceuticals by 87.5% in the first quarter. Osprey Private Wealth LLC now owns 9,439 shares of the biopharmaceutical company’s stock valued at $7,293,000 after purchasing an additional 4,404 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $664.52 on Monday. The company has a market cap of $70.25 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 1.47 and a beta of 0.24. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The firm’s fifty day moving average is $645.30 and its 200 day moving average is $721.99. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.22 earnings per share. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Analyst Ratings Changes

A number of research analysts have weighed in on REGN shares. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Barclays cut their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research note on Monday, May 18th. Finally, Leerink Partners restated a “market perform” rating and set a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $787.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.